These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 22127693)

  • 1. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
    Østergaard M; Emery P; Conaghan PG; Fleischmann R; Hsia EC; Xu W; Rahman MU
    Arthritis Rheum; 2011 Dec; 63(12):3712-22. PubMed ID: 22127693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.
    Conaghan PG; Emery P; Østergaard M; Keystone EC; Genovese MC; Hsia EC; Xu W; Rahman MU
    Ann Rheum Dis; 2011 Nov; 70(11):1968-74. PubMed ID: 21784729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
    Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
    Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
    Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C
    Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
    Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
    Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis.
    Emery P; van der Heijde D; Ostergaard M; Conaghan PG; Genovese MC; Keystone EC; Fleischmann R; Hsia EC; Xu W; Xu S; Rahman MU
    Ann Rheum Dis; 2011 Dec; 70(12):2126-30. PubMed ID: 21926186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.
    Baker JF; Ostergaard M; Emery P; Hsia EC; Lu J; Baker DG; Conaghan PG
    Ann Rheum Dis; 2014 Nov; 73(11):1968-74. PubMed ID: 23904470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
    Emery P; Fleischmann R; van der Heijde D; Keystone EC; Genovese MC; Conaghan PG; Hsia EC; Xu W; Baratelle A; Beutler A; Rahman MU
    Arthritis Rheum; 2011 May; 63(5):1200-10. PubMed ID: 21305524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state.
    Gandjbakhch F; Conaghan PG; Ejbjerg B; Haavardsholm EA; Foltz V; Brown AK; Møller Døhn U; Lassere M; Freeston J; Bøyesen P; Bird P; Fautrel B; Hetland ML; Emery P; Bourgeois P; Hørslev-Petersen K; Kvien TK; McQueen F; Ostergaard M
    J Rheumatol; 2011 Sep; 38(9):2039-44. PubMed ID: 21885514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
    Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
    Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P; Fleischmann RM; Doyle MK; Strusberg I; Durez P; Nash P; Amante E; Churchill M; Park W; Pons-Estel B; Xu W; Xu S; Wu Z; Hsia EC
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
    Peterfy C; Kremer J; Rigby W; Singer N; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
    J Rheumatol; 2020 Mar; 47(3):325-332. PubMed ID: 31154414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
    Weinblatt ME; Westhovens R; Mendelsohn AM; Kim L; Lo KH; Sheng S; Noonan L; Lu J; Xu Z; Leu J; Baker D; Bingham CO;
    Ann Rheum Dis; 2014 Dec; 73(12):2152-9. PubMed ID: 24001888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumab.
    Wagner C; Chen D; Fan H; Hsia EC; Mack M; Emery P; Fleischmann RM
    J Rheumatol; 2013 May; 40(5):590-8. PubMed ID: 23457387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
    Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H
    Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis.
    Forslind K; Svensson B
    Scand J Rheumatol; 2016; 45(2):99-102. PubMed ID: 26313244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
    Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
    Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
    Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Baker D; Ishii Y; Yoshinari T;
    Mod Rheumatol; 2016 Jul; 26(4):481-90. PubMed ID: 26474192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.